Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CSBR | US
-0.12
-2.63%
Healthcare
Biotechnology
31/07/2024
17/10/2024
4.44
4.53
4.58
4.42
Champions Oncology Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company through its Tumorgraft Technology Platform provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics a software platform and data tool that contains comprehensive information derived from research services and clinical studies and sold on an annual subscriptions basis. The company markets its products through internet word of mouth and sales force to patients and physicians. The company was formerly known as Champions Biotechnology Inc. and changed its name to Champions Oncology Inc. in April 2011. Champions Oncology Inc. was incorporated in 1985 and is headquartered in Hackensack New Jersey.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
Negative Momentum (Declining Price)
Price Below SMA10D
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
52.1%1 month
76.8%3 months
66.1%6 months
54.5%-
22.88
6.77
-21.41
0.29
26.26
1.28
-
-1.17M
60.36M
60.36M
-
9.45
-28.60
11.90
-432.46
1.50
3.96
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.54
Range1M
0.83
Range3M
1.85
Rel. volume
0.19
Price X volume
18.75K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Shattuck Labs Inc | STTK | Biotechnology | 1.38 | 65.86M | -4.83% | n/a | 3.45% |
Immuneering Corporation Class A Common Stock | IMRX | Biotechnology | 2.09 | 62.68M | -5.86% | n/a | 6.50% |
Kezar Life Sciences Inc | KZR | Biotechnology | 0.816 | 59.54M | -8.80% | n/a | 11.69% |
Omega Therapeutics Inc. Common Stock | OMGA | Biotechnology | 1.04 | 59.05M | 14.96% | n/a | 483.39% |
RAPT THERAPEUTICS INC. | RAPT | Biotechnology | 1.69 | 58.99M | -3.43% | n/a | 5.24% |
CEL-SCI Corporation | CVM | Biotechnology | 0.95 | 58.42M | -3.57% | n/a | 143.19% |
Allakos Inc | ALLK | Biotechnology | 0.65 | 57.75M | -1.28% | n/a | 47.30% |
CELU | CELU | Biotechnology | 2.6 | 57.16M | -6.47% | n/a | 159.71% |
Kronos Bio Inc | KRON | Biotechnology | 0.93 | 56.07M | -3.63% | n/a | 22.03% |
Actinium Pharmaceuticals Inc | ATNM | Biotechnology | 1.72 | 53.59M | 2.38% | n/a | 4.22% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.6 | 19.19M | 0.80% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 26.26 | 0.53 | Expensive |
Ent. to Revenue | 1.28 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 6.77 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 66.10 | 72.92 | Par |
Debt to Equity | -21.41 | -1.24 | Cheaper |
Debt to Assets | 0.29 | 0.25 | Par |
Market Cap | 60.36M | 3.78B | Emerging |